Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine

Krakow, Poland – September 11, 2023 – Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, is proud to announce its participation as one of the sponsors at the 31st Congress of the Polish Society of Hematology and Transfusion Medicine. This event is scheduled to take place from September 14th to 16th, 2023, in Katowice, Poland. 


Details on Ryvu activities through the conference are as follows:  

Ryvu Session  

Novel therapeutic options for patients with RR-AML and HR-MDS: focus on the first-in-class CDK8/19 inhibitor, RVU120 

Date and Time: September 14 (Thursday), 12:00 pm – 1:00 pm


  • Ewa Lech-Marańda (Institute of Hematology & Blood Transfusion) 
  • Eytan Stein (Memorial Sloan Kettering Cancer Center) 
  • Hendrik Nogai (Ryvu Therapeutics) 


Ryvu Presentations  

  • Oral Presentation 

Synergistic Effects of RUX and RVU120 Combination Therapy in Myeloproliferative Neoplasms 

Date and Time: September 14 (Thursday), 8:30 am – 10:00 am  

Presenter: Milena Mazan  

Session 3: Myeloproliferative Neoplasms 


  • Poster Presentations  

Date and Time: September 14 (Thursday), 6:15 pm – 7:00 pm 

  1. Safety and Efficacy Update from CLI120–001: a Phase 1b Dose Escalation Study in Relapse-Refractory Acute Myeloid Leukemia and High-Risk Myelodysplasia (P102)

Presenter: Noemi Angelosanto 

Poster Session 1: Myeloid Malignancies 

  1. RVU120 CDK8/19 Inhibitor Promotes Erythroid Differentiation in AML and HR-MDS Patients (P105)

Presenter: Agnieszka Sroka-Porada 

Poster Session 1: Myeloid Malignancies 


Ryvu Presentation 

RVU120 Represents a Novel Class of Agents Targeting Leukemia Stem Cells 

Date and Time: September 16 (Saturday), 12:55 pm – 1:15 pm 

Presenter: Tomasz Rzymski 

Session 43: Experimental Hematology 3: Pathogenesis and New Therapeutic Targets in Myeloid Malignancies 


Additionally, Ryvu Therapeutics will feature an exhibition booth where participants can engage with our experts to gain deeper insights into our research in the field of hemato-oncology.


If you are ready to advance hemato-oncology care with Ryvu, contact us at [email protected].